Loading...
•
Dec 31, 2020
Eli Lilly Q4 2020 Earnings Report
Eli Lilly reported strong Q4 2020 financial results, driven by volume growth and key growth products.
Key Takeaways
Eli Lilly's Q4 2020 revenue increased by 22% driven by volume growth of 24%. Excluding bamlanivimab revenue, revenue grew by 7%. EPS increased to $2.32 on a reported basis and $2.75 on a non-GAAP basis.
Revenue in Q4 2020 increased 22 percent, driven by volume growth of 24 percent. Excluding bamlanivimab revenue of $871 million, fourth-quarter 2020 revenue grew 7 percent.
Key growth products launched since 2014 contributed nearly 12 percentage points of revenue growth and represented approximately 48 percent of total revenue in the fourth quarter of 2020.
Fourth-quarter 2020 operating expenses increased 3 percent, driven by higher research and development investments, including expenses of $265 million to develop COVID-19 therapies.
Fourth-quarter 2020 earnings per share (EPS) increased to $2.32 on a reported basis and $2.75 on a non-GAAP basis.
Eli Lilly
Eli Lilly
Eli Lilly Revenue by Segment
Eli Lilly Revenue by Geographic Location
Revenue by Segment
Verzenio Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comOutside U.S. Revenue
CapyFin.com Forward Guidance
Eli Lilly has updated certain elements of its 2021 financial guidance on a reported basis. Earnings per share for 2021 are now expected to be in the range of $7.10 to $7.75 on a reported basis and are still expected to be in the range of $7.75 to $8.40 on a non-GAAP basis.
Positive Outlook
- Revenue growth is expected to be driven by volume from key growth products, including Trulicity, Taltz, Verzenio, Jardiance, Olumiant, Cyramza, Emgality, Tyvyt and Retevmo, as well as by COVID-19 therapies.
- Gross margin as a percent of revenue for 2021 is still expected to be approximately 77 percent on a reported basis and approximately 79 percent on a non-GAAP basis.
- Marketing, selling and administrative expenses for 2021 are still expected to be in the range of $6.2 billion to $6.4 billion.
- Research and development expenses for 2021 are still expected to be in the range of $6.5 billion to $6.7 billion, including approximately $300 million to $400 million of continued investment in COVID-19 therapies.
- The 2021 effective tax rate is still expected to be approximately 15 percent on both a reported basis and a non-GAAP basis.
Challenges Ahead
- Earnings per share for 2021 are now expected to be in the range of $7.10 to $7.75 on a reported basis
- Revenue growth is expected to be partially offset by lower revenue for products that have lost patent exclusivity.
- The company expects mid-single digit net price declines globally in 2021.
- Outside the U.S., the company expects net price declines in China, Japan, and Europe.
- Other income (expense) for 2021 is still expected to be expense in the range of $200 to $300 million on both a reported basis and on a non-GAAP basis.